X0306 4 2022-12-16 0 0001623715 Imago BioSciences, Inc. IMGO 0001861069 Tapper Amy E. C/O IMAGO BIOSCIENCES, INC. 303 TWIN DOLPHIN DRIVE, 6TH FLOOR REDWOOD CITY CA 94065 0 1 0 0 See Remarks Common Stock 2022-12-16 4 M 0 29461 2.1 A 148508 D Common Stock 2022-12-16 4 M 0 5952 2.19 A 154460 D Common Stock 2022-12-16 4 M 0 2380 2.27 A 156840 D Common Stock 2022-12-16 4 M 0 44500 2.52 A 201340 D Common Stock 2022-12-16 4 M 0 18009 1.52 A 219349 D Common Stock 2022-12-16 4 S 0 100302 35.7792 D 119047 D Stock Option (Right to buy) 2.1 2022-12-16 4 M 0 29461 0 D 2030-09-09 Common Stock 29461 23562 D Stock Option (Right to buy) 2.19 2022-12-16 4 M 0 5952 0 D 2019-11-17 2025-11-16 Common Stock 5952 0 D Stock Option (Right to buy) 2.27 2022-12-16 4 M 0 2380 0 D 2020-11-09 2026-11-08 Common Stock 2380 0 D Stock Option (Right to buy) 2.52 2022-12-16 4 M 0 44500 0 D 2021-01-01 2027-03-28 Common Stock 44500 8232 D Stock Option (Right to buy) 1.52 2022-12-16 4 M 0 18009 0 D 2029-04-09 Common Stock 18009 2729 D The transaction was executed in multiple trades in prices ranging from $35.77 to $35.79, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The Option vests with respect to 25% of the shares subject thereto on July 7, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from April 10, 2019 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Chief, Technical Operations On November 19, 2022, the Issuer entered into an Agreement and Plan of Merger, by and among the Issuer, Merck Sharpe & Dohme LLC and M-Inspire Merger Sub, Inc., providing for the merger of M-Inspire Merger Sub, Inc. with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly owned subsidiary of Merck Sharpe & Dohme LLC. In connection with the Merger, to mitigate the potential impact of Section 280G and Section 4999 of the Internal Revenue Code of 1986, as amended, the Reporting Person entered into the transactions disclosed on this Form 4. /s/ Hugh Rienhoff, as Attorney-in-Fact for Amy E. Tapper 2022-12-20